Mitsubishi UFJ Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $245K | Sell |
13,607
-5
| -0% | -$95 | ﹤0.01% | 1002 |
|
|
2026
Q1 | $296K | Sell |
13,612
-333
| -2% | -$6.45K | ﹤0.01% | 925 |
|
|
2025
Q4 | $297K | Buy |
13,945
+7,881
| +130% | +$166K | ﹤0.01% | 952 |
|
|
2025
Q3 | $117K | Buy |
6,064
+12
| +0.2% | +$214 | ﹤0.01% | 1024 |
|
|
2025
Q2 | $103K | Buy |
6,052
+3,414
| +129% | +$146K | ﹤0.01% | 1029 |
|
|
2025
Q1 | $168K | Buy |
2,638
+209
| +9% | +$22K | ﹤0.01% | 972 |
|
|
2024
Q4 | $307K | Buy |
2,429
+243
| +11% | +$29.8K | ﹤0.01% | 927 |
|
|
2024
Q3 | $273K | Sell |
2,186
-193
| -8% | -$26.7K | ﹤0.01% | 926 |
|
|
2024
Q2 | $376K | Sell |
2,379
-599
| -20% | -$76.9K | ﹤0.01% | 891 |
|
|
2024
Q1 | $386K | Sell |
2,978
-130
| -4% | -$15.9K | ﹤0.01% | 900 |
|
|
2023
Q4 | $291K | Buy |
3,108
+1,227
| +65% | +$118K | ﹤0.01% | 973 |
|
|
2023
Q3 | $228K | Buy |
1,881
+43
| +2% | +$4.86K | ﹤0.01% | 1008 |
|
|
2023
Q2 | $210K | Sell |
1,838
-673
| -27% | -$86.8K | ﹤0.01% | 1033 |
|
|
2023
Q1 | $346K | Buy |
2,511
+145
| +6% | +$18.8K | ﹤0.01% | 969 |
|
|
2022
Q4 | $295K | Sell |
2,366
-1,271
| -35% | -$147K | ﹤0.01% | 980 |
|
|
2022
Q3 | $402K | Buy |
3,637
+57
| +2% | +$5.75K | ﹤0.01% | 924 |
|
|
2022
Q2 | $268K | Sell |
3,580
-356
| -9% | -$26.2K | ﹤0.01% | 1011 |
|
|
2022
Q1 | $307K | Buy |
3,936
+425
| +12% | +$32.5K | ﹤0.01% | 995 |
|
|
2021
Q4 | $317K | Sell |
3,511
-467
| -12% | -$39.9K | ﹤0.01% | 1000 |
|
|
2021
Q3 | $368K | Buy |
3,978
+102
| +3% | +$7.86K | ﹤0.01% | 983 |
|
|
2021
Q2 | $301K | Sell |
3,876
-14,495
| -79% | -$1.1M | ﹤0.01% | 1037 |
|
|
2021
Q1 | $1.37M | Buy |
18,371
+2,182
| +13% | +$201K | 0.01% | 764 |
|
|
2020
Q4 | $2.76M | Buy |
16,189
+1,318
| +9% | +$195K | 0.02% | 584 |
|
|
2020
Q3 | $2.09M | Buy |
14,871
+2,045
| +16% | +$311K | 0.02% | 572 |
|
|
2020
Q2 | $2.06M | Buy |
12,826
+928
| +8% | +$126K | 0.02% | 536 |
|
|
2020
Q1 | $1.16M | Sell |
11,898
-1,803
| -13% | -$206K | 0.02% | 589 |
|
|
2019
Q4 | $1.78M | Buy |
13,701
+1,468
| +12% | +$148K | 0.02% | 569 |
|
|
2019
Q3 | $921K | Buy |
12,233
+11,238
| +1,129% | +$1.33M | 0.02% | 641 |
|
|
2019
Q2 | $151K | Sell |
995
-389
| -28% | -$47.3K | ﹤0.01% | 864 |
|
|
2019
Q1 | $165K | Buy |
1,384
+165
| +14% | +$21.2K | ﹤0.01% | 817 |
|
|
2018
Q4 | $130K | Sell |
1,219
-264
| -18% | -$33K | ﹤0.01% | 809 |
|
|
2018
Q3 | $240K | Buy |
+1,483
| New | +$203K | ﹤0.01% | 754 |
|
|
2013
Q3 | – | Sell |
-6,800
| Closed | -$259K | – | 832 |
|
|
2013
Q2 | $259K | Buy |
+6,800
| New | +$243K | 0.01% | 662 |
|
Other funds holding SRPT
EAM
Mitsubishi UFJ Asset Management's SRPT Position: Q2 2026 in Review
Mitsubishi UFJ Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 0.04% in Q2 2026, selling an estimated $95 and leaving 13,607 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.
Mitsubishi UFJ Asset Management first reported a position in SRPT in Q2 2013 and has held it in 33 quarters since. The position peaked at $2.76M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Mitsubishi UFJ Asset Management held 13,607 shares of Sarepta Therapeutics worth $245K as of Q2 2026.
- Mitsubishi UFJ Asset Management sold 5 Sarepta Therapeutics shares in Q2 2026, an estimated $95.
- Sarepta Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1002 holding.
- Mitsubishi UFJ Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 33 quarters since.
- Mitsubishi UFJ Asset Management's Sarepta Therapeutics position peaked at $2.76M in Q4 2020.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.